A Phase II, Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Selective Progesterone Receptor Modulator Proellex (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
Latest Information Update: 05 Sep 2014
At a glance
- Drugs Telapristone (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Repros Therapeutics
- 14 Apr 2009 New source identified and integrated (ClinicalTrials.gor record NCT00882258).
- 01 Apr 2007 Status changed from in progress to completed.
- 20 Jun 2006 New trial record.